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Summary
The p73 gene codes for various diﬀerent protein isoforms. They include proteins expressed under the control of the
P1 promoter that contain a transactivation domain and are similar in function to p53 (TAp73 isoforms), as well as
proteins regulated by the P2 promoter that lack this domain and function as dominant negative inhibitors of TAp73
and p53 (DNp73 isoforms). Whereas TAp73 functions as a tumor suppressor with pro-apoptotic function, DNp73 is
likely to prevent the induction of apoptosis in tumor cells and to participate in oncogenesis. Here we used a loss-of-
function strategy to assess the role of DNp73 in SH-SY5Y neuroblastoma cells. An antisense oligonucleotide
designed to target DNp73 mRNA, but not TAp73, was used to eﬀectively downregulate this transcript. DNp73
downregulation was accompanied by increased levels of the pro-apoptotic BH3 family member PUMA at the
mRNA and protein level, and by conformational activation of BAX which translocated to mitochondria. These
DNp73 antisense-mediated alterations led to the induction of apoptosis as detected by decreased cell viability,
augmented DNA fragmentation and increased caspase-3 activity in cell lysates. Our results demonstrate the cy-
toprotective role of DNp73 in neuroblastoma and suggest its use as a target for molecular intervention therapy.
Introduction
p53 and p73 proteins have a relatively high sequence
homology to each other and may act as transcription
factors with common target sequences whose tran-
scriptional activation can lead to cell cycle-arrest and
apoptosis. p53 has a tumor-suppressor function as re-
vealed by studies with knockout mice and based on data
with primary tumors, which demonstrate its inactivation
in more than 50% of all human cancers [1]. Comparable
observations have not been reported for p73 [2,3],
indicating that the role of p73 in neoplastic transfor-
mation is less well deﬁned, likely due to the co-existence
of distinct p73 isoforms with opposing functions, some
acting as tumor suppressors and others as oncogenes.
In contrast to p53, the p73 gene codes for various
mRNAs which arise according to alternative splicing
and are under the control of at least two promoters [3].
One can distinguish between two major types of p73
isoforms, long and short, which diﬀer in the amino-
terminal sequence. The long isoforms are transcrip-
tionally regulated by the P1 promoter and contain the
transactivation domain encoded by exons 2 and 3
(TAp73), whereas the short isoforms arise upon activa-
tion of the P2 promoter and comprise, instead of the TA
domain, a smaller sequence derived from an alternative
3¢-exon (DNp73). Within each of these two major types a
variety of other proteins (a–g) exist that arise from dif-
ferential carboxy-terminal splicing. Whereas the TAp73-
isoforms positively regulate several p53-responsive genes
[3–5], the DNp73-isoforms behave as dominant negative
inhibitors of both the p53- and the TA-dependent acti-
vation of these genes [6–13]. DNp73 has been shown to
act as an oncogene [9] and to be up-regulated in human
tumors relative to normal tissues [10].
p73 locates to chromosome 1p36, a locus prone to loss
of heterozygosity in various tumor types, particularly in
neuroblastoma [3] which is the most frequent solid tu-
mor in children under 5 years of age [14]. To date,
neuroblastoma is the only tumor type in which expres-
sion of DNp73 has been clearly shown to be an adverse
prognostic marker [15], and investigations into the
prognostic value of the diﬀerent p73 isoforms in other
cancer types are underway. In the present study we used
antisense oligonucleotides targeting a sequence present
in DNp73, but not in TAp73, to assess the role of these
short p73 isoforms in SH-SY5Y neuroblastoma cells.
Downregulation of DNp73 led to an increase in the level
of PUMA mRNA and protein, and to conformational
activation of BAX. These alterations resulted in de-
creased viability by induction of apoptosis.
Material and methods
Treatment of cells with oligonucleotides
SH-SY5Y neuroblastoma cells were cultured in RPMI-
1640 (Hyclone Europe, Ltd., Cramlington, UK), sup-
plemented with 10% FCS (Hyclone Europe, Ltd.),
2 mM L-glutamine, 50 IU/ml penicillin, 50 lg/ml
streptomycin and 20 lg/ml gentamicine, and maintained
at 37 C in a humidiﬁed atmosphere containing 5%
CO2. Oligonucleotides with a full phosphorothioate
backbone (Microsynth, Balgach, Switzerland) were deliv-
ered into cells in the form of complexes with Lipofectin
Journal of Neuro-Oncology (2005) 72: 29–34  Springer 2005
(Life Technologies, Glasgow, UK) as described in detail
elsewhere [16]. The sequences were as follows: 7001, 5¢-
CCCATCTCCCTTAGTTCTGT-3¢; sc-7001a, 5¢-TA-
ACCGTTTCTTCCTCGTCC-3¢; sc7001b, 5¢-
GTTACCCTCCTTACTCGCTT-3¢. A BLAST search
of the NCBI database revealed no homology of these
sequences to other known human genes.
Real-time PCR
Total RNA isolation, cDNA synthesis and real-time
PCR were performed as previously described [17] with
modiﬁcations. DNase was included during RNA isola-
tion in order to eliminate any contaminating genomic
DNA. The ampliﬁcation of DNp73 cDNA was per-
formed using 5¢-AAAAGCGAAAATGCCAACAA-3¢
as forward primer, 5¢-GCAGGAGCCGAGGATGC-3¢
as reverse primer and 5¢-CGGCCCGCATGTTCCCC-3¢
as Taqman probe (Applied Biosystems, Foster City,
CA). These bind to the untranslated region of the 3¢
exon from the p73 gene which is characteristic and
exclusive for all the DNp73 isoforms, independent of
their carboxy-terminal sequence. A BLAST search of
the NCBI database revealed no homology of the primers
and probe sequences to other known human genes.
Ampliﬁcation of rRNA, used as an internal standard,
was performed in 100-times further diluted cDNA sus-
pensions and the calibration curve method was used for
relative quantiﬁcation of DNp73. For PUMA mRNA,
Assay-on-Demand (Applied Biosystems) primers and
probe were used and the data were quantiﬁed by the
comparative CT method. The mRNA level in untreated
cells was taken as 100%, upon correction for the internal
standard.
Western blotting
Western blot analysis was performed as previously de-
scribed with modiﬁcations [17]. The blots were incu-
bated during 2 h at room temperature (or overnight at
4 C) with goat anti-human PUMAa (N-19) polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). a-tubulin detected with a mouse monoclonal
antibody (TU-02, Santa Cruz Biotechnology) was used
to assure comparable protein loading. To detect the
primary antibody, blots were incubated with rabbit anti-
goat or rabbit anti-mouse immunoglobulin peroxidase
conjugates, respectively (Sigma, St. Louis, MO) for 1 h
at room temperature.
Immunocytochemistry
Floating and adherent cells were removed from culture
6-well plates and resuspended in 100 ll PBS. Upon
subsequent cytospin centrifugation, the cells were ﬁxed
by adding 100 ll of Cytoﬁx/Cytoperm solution (BD
Biosciences, San Diego, CA), washed with PermWash
solution (BD Biosciences) and incubated with rabbit
anti-human Bax (N-20) polyclonal antibody (Santa
Cruz Biotechnology) for 30 min. After three washes
with PermWash solution, cells were incubated with goat
anti-rabbit-FITC (Sigma) followed by 1 lg/ml Hoechst
33342 (Sigma) in PBS. Finally, cells were washed twice
with PBS, dipped in distilled water and mounted with
Mowiol (Calbiochem, La Jolla, CA). The preparations
were analysed under a DM IRB E Leica microscope
(Leica, Wetzlar, Germany) equipped with a TCS4D
confocal laser scanning system (Leica Lasertechnik,
Heidelberg, Germany) including a UV-laser (Enterprise
Argon ion laser, model 651, Coherent Inc., Santa Clara,
CA, USA), a laser for visible excitation light (model 543
Argon-Krypton-laser, Omnichrome Inc. Chino, CA,
USA) and SCANware software (Leica, Wetzlar, Ger-
many). Images were processed using Adobe Photoshop
software (Adobe Systems Inc., San Jose, CA, USA) or
an Octane workstation (Solikon Graphics Inc., Moun-
tain View, CA, USA) for the DIC pictures.
Measurement of cell viability
Cell viability was determined by use of a colorimetric
assay based on the reduction of the tetrazolium salt
MTT as described [17]. Cells were plated in 96-well
plates (7500 cells/well), incubated overnight, treated in
the absence or presence of various oligonucleotide
concentrations during 6 h and, after renewal of the
culture medium, further incubated for up to 72 h.
Caspase-3 assay
Caspase-3-like protease activity in cell lysates was
analysed by use of the Caspase-3 Colorimetric Assay Kit
(Alexis Corporation, Lausen, Switzerland) following
manufacturer’s recommendations. Cleavage of the la-
beled substrate DEVD-pNA was monitored at 405 nm
using a SPECTRAmax 340 microplate reader. The
caspase-3-like protease activity in lysates from apoptotic
cells was calculated as fold increase of the absorbance
signal obtained with lysates of untreated (viable) cells
kept under identical conditions.
Measurement of apoptosis by ﬂow cytometry
Cells were harvested 72 h after the start of oligonu-
cleotide treatment (400 nM ﬁnal concentration, 6 h
transfection), washed with PBS containing 5 mM
EDTA and ﬁxed with 100% ice-cold ethanol. Upon
treatment with phosphate-citrate buﬀer for 30 min to
extract degraded DNA [18], the ﬁxed cells were again
washed with 5 mM EDTA in PBS and incubated with
5 lg/ml RNAse A for 30 min. Thereafter, propidium
iodide was added to achieve a ﬁnal concentration of
50 lg/ml and the cells were subjected to ﬂow cytometry
using a FACScalibur ﬂow cytometer (Becton Dickinson,
Mountain View, CA). A total of 10,000 events were
analysed and clusters as well as cell debris were elimi-
nated by appropriate gating. The subpopulation of
apoptotic cells with ﬂuorescence signals lower than that
of cells in the G1 phase (sub-G1 peak due to fragmented
DNA) [19] was determined using the CellQuest software
(Becton Dickinson).
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Results
Downregulation of DNp73 mRNA by antisense
oligonucleotide 7001
To study the role of DNp73 isoforms in tumor cells, we
screened for an antisense oligonucleotide to eﬀectively
and speciﬁcally downregulate these transcripts. Seven
target sequences were validated, all of them located in
the untranslated region of the 3¢ exon of the TP73 gene
which is present in all DNp73 but not in the TAp73
isoforms. All sequences were expected to be accessible to
oligonucleotide annealing as predicted by the RNAdraw
program [20]. Oligonucleotide 7001 targeting nucleo-
tides 16–35 of the human DNp73 mRNA (NCBI
accession number AB055065, a isoform) was the most
eﬀective in downregulating DNp73 in various cancer cell
types (data not shown). While oligonucleotide 7001 led
to a more than 80% reduction of target expression, two
scrambled sequence control oligonucleotides (sc7001a
and sc7001b) did not inhibit gene expression (Figure 1).
Downregulation of the DNp73 transcript was observed
as early as 2 h after addition of oligonucleotide 7001
(data not shown). The levels of the corresponding pro-
teins in untreated cells were below the detection
threshold of Western blotting using commercially
available antibodies, which precluded the measurement
of antisense eﬀects on the protein level.
A recent technology in targeted gene silencing takes
advantage of the process of RNA interference by use of
short double-stranded RNA (siRNA, small interfering
RNA) [21]. Our own results with siRNA targeting the
site of 7001 hybridization in the DNp73 mRNA revealed
lower antisense activity compared to oligonucleotide
7001 (data not shown).
Transcriptional activation of PUMA upon
downregulation of DNp73
DNp73 may function as a dominant negative form of
TAp73 and p53. Very recent work by other authors has
shown that overexpression of DNp73 is able to inhibit
TAp73- and p53-induced apoptosis by preventing the
transcriptional activation of the BH3-only protein
PUMA (p53-upregulated modulator of apoptosis) [4].
We hypothesized that if endogenous DNp73 would
function in a similar way in SH-SY5Y cells, then its
downregulation would result in transcriptional activa-
tion of PUMA. The level of PUMA mRNA increased
with time during treatment with oligonucleotide 7001
(Figure 2A). Transcriptional activation of PUMA in-
duced by antisense oligonucleotide 7001 (Figure 2) was
accompanied by increased protein expression (Figure 3).
Although at later time points treatment with the control
oligonucleotides also slightly increased the expression of
PUMA mRNA, this nonantisense eﬀect was not ob-
served on the functionally more relevant protein level
(Figure 3). As shown in Figure 2B, NOXA, another
BH-3 only protein, which is regulated by p53 on the
transcriptional level [22], was not transcriptionally
activated upon DNp73 downregulation.
Silencing of DNp73 is associated with conformational
activation of Bax
PUMA may elicit conformational activation of the pro-
apoptotic Bcl-2 family member Bax [4]. To examine this
possibility under conditions when PUMA is transcrip-
tionally activated by downregulation of DNp73, we
studied the conformation status of Bax using an
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Figure 1. Antisense oligonucleotide 7001 downregulates DNp73
mRNA in neuroblastoma cells. SH-SY5Y cells were incubated with
600 nM oligonucleotide 7001 or the corresponding scrambled sequence
controls sc7001a and sc7001b, and harvested after a 20 h incubation.
The relative levels of DNp73 mRNA were quantiﬁed by real-time PCR.
Data are shown as mean ± SD of at least three independent experi-
ments.
Figure 2. Antisense oligonucleotide 7001 increases the level of PUMA mRNA. (A) SH-SY5Y cells were incubated with 600 nM oligonucleotides
7001, sc7001a or sc7001b, and harvested after the indicated time periods. PUMA mRNA quantiﬁcation was performed by real-time PCR. (B)
SH-SY5Y cells were incubated with 600 nM oligonucleotide 7001 and harvested after the indicated time periods. PUMA and NOXA mRNA
quantiﬁcation was performed by real-time PCR. Data are shown as mean ± SD of at least three independent experiments.
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N-terminus-speciﬁc antibody, which only has access to
its epitope if the protein presents in an activated con-
formation. In untreated SH-SY5Y control cells, the
immunoﬂuorescence signal upon staining with the con-
formation-dependent anti-Bax antibody could not be
distinguished from background (not shown). As shown
in Figure A, treatment with oligonucleotide 7001 re-
sulted in a clear ﬂuorescence signal, indicating that the
antibody’s epitope was no longer occluded and that Bax
had undergone a conformational change. The observed
punctuate staining pattern suggests that activated Bax
translocated to mitochondria. Moreover, cells positive
for activated Bax were those in which condensed nuclei
morphology was observed (Figure 4B), suggesting that
activation of Bax initiated the apoptotic cascade. Bax
activation occurred in the absence of a measurable in-
crease in Bax protein level (not shown).
SH-SY5Y cell viability is impaired upon treatment with
DNp73 antisense
To study the eﬀect of DNp73 downregulation on the
survival of SH-SY5Y cells, diﬀerent methods were used.
As shown in Figure 5A, treatment with oligonucleotide
7001 speciﬁcally induced caspase-3-like activity that is
indicative for the onset of apoptosis. Flow cytometry
analysis was used to quantify the rate of apoptosis by
measuring the sub-G1 population upon the various
treatments. Figure 5B shows that downregulation of
DNp73 using oligonucleotide 7001 induced apoptosis in
a signiﬁcant fraction of the total cell population, which
correlated with a concentration-dependent reduction of
cell viability measured in colorimetric assays (Fig-
ure 5C). In all experiments, the unspeciﬁc toxicity of the
control oligonucleotides sc7001a and sc7001b was sig-
niﬁcantly lower than the pro-apoptotic eﬀect of the
DNp73-speciﬁc antisense oligonucleotide 7001.
Discussion
The co-existence of tumor suppressor and oncogene
isoforms encoded by the p73 gene hampers the inter-
pretation of data obtained in p73 knockout mice [2] or
with antisense approaches targeting sequences common
to both TA- and DNp73 isoforms [11]. In the only study
published so far with a DNp73-speciﬁc antisense oligo-
nucleotide, downregulation of the protein induced
apoptosis in colon carcinoma cells, either upon expres-
sion of exogenous p53 or induction of DNA damage
[10]. Our data reveal that 7001 is a highly eﬀective
DNp73 antisense molecule and that silencing of these
transcripts induces apoptosis in neuroblastoma cells.
Antisense 7001 is a ﬁrst generation phosphorothioate
oligonucleotide, the most commonly used type of anti-
sense chemistry [23] and the one which could prove to be
eﬀective in clinical trials [24]. Nevertheless, phosphoro-
thioate oligonucleotides are also known to exhibit se-
quence-independent nonantisense-related eﬀects [25].
Since the quantiﬁcation of unspeciﬁcity is of particular
relevance in cell viability/apoptosis experiments, we in-
cluded two scrambled sequence control oligonucleotides
in our study. Independent of the method used (caspase-3-
like activity, ﬂow cytometry, cell viability assay), the
eﬀect of oligonucleotide 7001 on cell viability and
apoptosis induction was signiﬁcantly stronger than those
of the control oligonucleotides, indicating that it pri-
marily resulted from DNp73 downregulation.
Several gain-of-function studies [7–13], including one
performed with SH-SY5Y cells [6], demonstrated that
Figure 3. Antisense oligonucleotide 7001 increases the level of PUMA protein. SH-SY5Y cells were incubated with 300 nM oligonucleotides
7001, sc7001a or sc7001b, and harvested after the indicated time periods before PUMA protein level was quantitated by Western blotting.
Figure 4. Antisense oligonucleotide 7001 induces conformational activation of Bax. SH-SY5Y cells were incubated with 300 nM oligonucleotide
7001 for 20 h. Staining of activated Bax (A) and cell nuclei (B) was performed as described under ‘Materials and Methods’.
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DNp73 proteins are able to act on TAp73/p53 in a
dominant-negative fashion by blocking their transacti-
vation activity and ability to induce apoptosis. These
studies were corroborated by investigations on the
neuronal anomalies induced by cytomegalovirus which
revealed that an accumulation of DNp73 is involved in
the apoptosis-blocking eﬀect of this virus [12]. We be-
lieve that downregulating endogenous DNp73 released
its repressing eﬀect on TAp73 and/or p53. The inhibi-
tion of p53/TAp73 could occur either via a physical
interaction between DNp73 and TAp73/p53, or through
competition for the DNA-binding site of the p53/TAp73
targets [6]. SH-SY5Y cells express both TAp73 and wt-
p53 [5,7], making a clear distinction between these two
possible targets of DNp73 diﬃcult. Since p53 is func-
tionally inactivated by sequestration into the cytosol in
SH-SY5Y cells [5] and no activation could be observed
upon DNp73 antisense treatment using an ELISA-based
assay (data not shown), we can exclude that our
observations are due to a p53-mediated eﬀect.
TAp73 and p53 are both able to induce apoptosis,
though there are diﬀerences in the functional processes
favored by the two proteins. Whereas p53 induces
apoptosis by its ability to directly act on mitochondria
[26] and through transcriptional activation of both
PUMA and NOXA [27], TAp73-induced apoptosis
seems to occur in the absence of a direct eﬀect on
mitochondria via an exclusively PUMA-mediated
pathway [4]. The speciﬁc transcriptional activation of
PUMA induced by DNp73 antisense treatment was
associated with a conformational change of Bax, a
ﬁnding which is in agreement with previous data
showing that overexpression of PUMA is able to acti-
vate Bax and promote its mitochondrial translocation
[4]. Although it is known that PUMA, like other BH3-
only proteins, requires Bax (or Bak) to induce apoptosis
[22], the molecular mechanism of this interaction is not
yet fully understood. Since the BH3-only proteins bind
to a cleft formed by the BH1 and BH2 domains of anti-
apoptotic Bcl-2 family members [27], it is conceivable
that Bax-activation by PUMA requires additional pro-
teins, i.e. Bcl-2 or Bcl-xL. The similarities between the
TAp73-induced onset of cell death [4] and our data on
the activation of the apoptosis machinery by DNp73
antisense are striking. Both processes seem to be
dependent on the transcriptional activation of PUMA
(but not NOXA) and involve a conformational (not
transcriptional) activation of Bax. These similarities
strongly suggest that by depleting the pool of endoge-
nous DNp73, its repressing eﬀect on TAp73 could be
diminished, resulting in restoration of the pro-apoptotic
function of this protein.
Neuroblastoma is characterized by a broad clinical
spectrum, including diseases with spontaneous regres-
sion and highly aggressive tumors [14], which points to
the existence of a broad range of oncogenic determi-
nants. Expression of DNp73 correlates with poor overall
and decreased disease-free survival in neuroblastoma
patients independent of age, site of the primary tumor,
stage and MYCN ampliﬁcation [15]. Our data conﬁrm
the relevance of DNp73 as a survival factor in neuro-
blastoma and shed new light on its biological function
and implication in apoptosis resistance.
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